13th Annual Global Embolization Symposium & Technologies
Purpose : This study aimed to explore the efficacy and safety of drug-eluting beads-transcatheter arterial chemoembolization (DEB-TACE) with or without iodine-125 in treating advance non-small-cell lung cancer (NSCLC) patients.
Material and Methods : 25 NSCLC patients underwent DEB-TACE were consecutively enrolled, among which 17 cases received followed iodine-125 implantation. Treatment response, overall survival (OS), biochemical indexes and safety profiles were recorded and analyzed.
Results : 0 (0.0%), 13 (54.2%), 9 (37.5%) and 2 (8.3%) patients realized complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) respectively, and the objective response rate (ORR) and disease control rate (DCR) were 54.2% and 91.7%. The median OS was 12.6 (95%CI: 7.8-17.5) months. No difference of treatment response or OS was observed between DEB-TACE treatment alone and DEB-TACE plus iodine-125 treatment. Predictive factors analysis revealed tumor size correlated with worse OS. Besides, chest distress grade and dyspnea grade were decreased after DEB-TACE procedure, while clinical symptoms were not changed after iodine-125 implantation. The common adverse events (AEs) were fever (32.0%), pain (12.0%) by DEB-TACE treatment, and common AE was pain (26.7%) by iodine-125 implantation.
Conclusions : DEB-TACE with or without iodine-125 treatment is efficient and tolerable in treating advanced NSCLC patients, which provides an option for advanced NSCLC management.